Literature DB >> 27456981

Dinutuximab: A Novel Immunotherapy in the Treatment of Pediatric Patients With High-Risk Neuroblastoma [Formula: see text].

Joy Bartholomew1, Tanea Washington2, Sharon Bergeron3, Danelle Nielson4, Jennifer Saggio5, Lindsay Quirk2.   

Abstract

Therapy combining dinutuximab with granulocyte macrophage colony stimulating factor, interleukin 2, and isotretinoin has significant side effects; however, these complications are generally predictable and can be managed proactively.

Entities:  

Keywords:  immunotherapy; infusion management; patient safety

Year:  2016        PMID： 27456981     DOI： 10.1177/1043454216659448

Source DB:  PubMed          Journal:  J Pediatr Oncol Nurs        ISSN： 1043-4542            Impact factor:   1.636


  4 in total

1.  Development of a dinutuximab delivery system using silk foams for GD2 targeted neuroblastoma cell death.

Authors:  Kimberly J Ornell; Bill Chiu; Jeannine M Coburn
Journal:  J Biomed Mater Res A       Date:  2020-12-10       Impact factor: 4.854

Review 2.  New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.

Authors:  Isabel Corraliza-Gorjón; Beatriz Somovilla-Crespo; Silvia Santamaria; Jose A Garcia-Sanz; Leonor Kremer
Journal:  Front Immunol       Date:  2017-12-21       Impact factor: 7.561

3.  MiR-20a-5p suppresses tumor proliferation by targeting autophagy-related gene 7 in neuroblastoma.

Authors:  Yongbo Yu; Jie Zhang; Yaqiong Jin; Yeran Yang; Jin Shi; Feng Chen; Shujing Han; Ping Chu; Jie Lu; Huanmin Wang; Yongli Guo; Xin Ni
Journal:  Cancer Cell Int       Date:  2018-01-04       Impact factor: 5.722

Review 4.  From Hematopoietic Stem Cell Transplantation to Chimeric Antigen Receptor Therapy: Advances, Limitations and Future Perspectives.

Authors:  Elisaveta Voynova; Damian Kovalovsky
Journal:  Cells       Date:  2021-10-22       Impact factor: 6.600
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.